Orion and Bayer jointly present new data in prostate cancer from the Darolutamide ARAMIS study
First presentation of data from the pivotal Phase III ARAMIS trial with the investigational compound darolutamide in patients with advanced prostate cancer that has not yet metastasized will be…
